Daiichi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI, and what generic alternatives to DAIICHI drugs are available?
DAIICHI has four approved drugs.
There are twenty-five US patents protecting DAIICHI drugs.
There are three hundred and nineteen patent family members on DAIICHI drugs in forty-five countries and twenty-five supplementary protection certificates in sixteen countries.
Summary for Daiichi
| International Patents: | 319 |
| US Patents: | 25 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
| PTAB Cases with Daiichi as patent owner: | See PTAB cases with Daiichi as patent owner |
Drugs and US Patents for Daiichi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | 9,149,532 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 7,893,075 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 9,585,892 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Daiichi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi | FLOXIN OTIC | ofloxacin | SOLUTION/DROPS;OTIC | 020799-001 | Dec 16, 1997 | 5,401,741 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Peru | 20081226 | ⤷ Try a Trial |
| Japan | 2018515490 | ⤷ Try a Trial |
| New Zealand | 595382 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | 612 | Finland | ⤷ Try a Trial | |
| 1405852 | C01405852/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015 |
| 1429780 | 122012000070 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
